R-107
Treatment-Resistant Depression (TRD)
Key Facts
About Tasman Therapeutics
Tasman Therapeutics is a late-stage private biotech advancing R-107, a proprietary oral extended-release ketamine tablet for Treatment-Resistant Depression. With Phase 2 trials complete and an open IND for Phase 3, the company is preparing for pivotal studies with a clear regulatory pathway. As an affiliate of the established Douglas Pharmaceuticals, Tasman benefits from deep formulation expertise, strong IP protection until at least 2037, and a seasoned leadership team, positioning it to potentially capture a significant share of the growing TRD market with a convenient, at-home monotherapy.
View full company profileAbout Tasman Therapeutics
Tasman Therapeutics is a late-stage private biotech advancing R-107, a proprietary oral extended-release ketamine tablet for Treatment-Resistant Depression. With Phase 2 trials complete and an open IND for Phase 3, the company is preparing for pivotal studies with a clear regulatory pathway. As an affiliate of the established Douglas Pharmaceuticals, Tasman benefits from deep formulation expertise, strong IP protection until at least 2037, and a seasoned leadership team, positioning it to potentially capture a significant share of the growing TRD market with a convenient, at-home monotherapy.
View full company profileTherapeutic Areas
Other Treatment-Resistant Depression (TRD) Drugs
| Drug | Company | Phase |
|---|---|---|
| CYC-126 | Cyclerion Therapeutics | Phase 1 |
| DOT | Motif Neurotech | Pre-clinical |
| FMP374 | FundaMental Pharma | Preclinical |
| GH001 | GH Research | Phase 2b/3 |
| COMP360 Psilocybin Therapy | Compass Pathways | Phase 3 |
| Ketamir-2 (Ketamir) | MIRA Pharmaceuticals | Phase 1 |